NRAS and acute myeloid leukemia: The co-mutational landscape of mBCOR AML (Figure 1F) was characterized by high rates of mutation in DNMT3A (39%), RUNX1 (30%), TET2 (23%), NRAS (20%), BCORL1 (17%), and STAG2 (17%).